February 9, 2018

pSivida to Present at the 2018 BIO CEO & Investor Conference

WATERTOWN, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy Lurker, President and Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the Annual BIO CEO & Investor Conference on Tuesday, February 13, 2018, at 2:30 p.m. ET.  The conference will be held in New York, NY.

A live audio and/or webcast and subsequent archived replay of pSivida's presentation may be accessed via the Investors section of the Company's website under "Resources - Events & Presentations" at www.psivida.com. The replay will be available for 90 days after the event.

About pSivida Corp.
pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a miniaturized insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. In January 2018, pSivida filed an NDA with the FDA for its lead product candidate, Durasert™ insert for posterior segment uveitis, which is being independently developed. Two pivotal Phase 3 studies with Durasert achieved their primary efficacy endpoint of prevention of recurrence of uveitis at six months of follow-up with statistical significance. pSivida's pre-clinical development program is focused on using its core platform technology Durasert to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida, please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.

Contact:

EVC Group

Michael Polyviou/Doug Sherk - Investors
mpolyviou@evcgroup.comdsherk@evcgroup.com 
212.850.6020; 646-445-4800

Thomas Gibson - Media
tom@tomgibsoncommunications.com 
201-476-0322

Primary Logo

Source: pSivida Corp.

News Provided by Acquire Media


Close window | Back to top

Copyright 2018 EyePoint Pharmaceuticals